Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.15USD
20 Apr 2018
Change (% chg)

$-0.07 (-1.66%)
Prev Close
$4.22
Open
$4.17
Day's High
$4.22
Day's Low
$4.13
Volume
24,767
Avg. Vol
104,109
52-wk High
$7.24
52-wk Low
$2.26

Chart for

About

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $227.57
Shares Outstanding(Mil.): 54.84
Dividend: --
Yield (%): --

Financials

  CDXC.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.34 -- --
ROI: -50.46 -0.74 13.19
ROE: -51.81 -2.80 15.00

BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17

* Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION

Mar 08 2018

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

Feb 16 2018

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

Feb 12 2018

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT

Jan 22 2018

BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore

* CHROMADEX AND WATSONS EXPAND PARTNERSHIP WITH TRU NIAGEN™ RETAIL LAUNCH IN SINGAPORE Source text for Eikon: Further company coverage:

Jan 08 2018

BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders

* CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [http://bit.ly/2kt48c4] Further company coverage:

Dec 14 2017

BRIEF-ChromaDex Corp qtrly ‍reported net sales of $6.1 million from continuing operations

* Chromadex Corp - qtrly ‍reported net sales of $6.1 million from continuing operations compared to $3.9 million for Q3 of 2016​ Source text: (http://bit.ly/2zpFLpg) Further company coverage:

Nov 09 2017

BRIEF-ChromaDex Q3 loss per share $0.07 from continuing operations

* Q3 sales rose 55 percent to $6.1 million Source text for Eikon: Further company coverage:

Nov 09 2017

BRIEF-Chromadex announces $23 mln private placement of common stock

* Chromadex announces $23 million private placement of common stock

Nov 06 2017

BRIEF-Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln

* Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing Source text: [http://bit.ly/2z2cq3P] Further company coverage:

Oct 31 2017

Earnings vs. Estimates